Abvc Biopharma (ABVC) EBT Margin (2010 - 2025)
Abvc Biopharma's (ABVC) quarterly EBT Margin came in at 394.74% in Q4 2025, up 4090984.0% YoY from N/an in Q4 2024, and up 100.97% on a QoQ basis from 40515.11% in Q4 2024.
Abvc Biopharma (ABVC) EBT Margin (2010 - 2025) Analysis & Trends
Abvc Biopharma (ABVC) has 13 years of EBT Margin data on file, last reported at 394.74% in Q4 2025.
- Quarterly EBT Margin rose 4090984.0% year-over-year to 394.74% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 3265.53% (up 431924.0% YoY) and the FY2025 annual result came in at 26284.04%, down 2523033.0% from the prior year.
- EBT Margin grew to 394.74% in Q4 2025, from 40515.11% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 1496.5% in Q4 2021 to a low of 242959.92% in Q1 2024.
- A 5-year average of 24094.65% and a median of 1981.75% in 2021 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2024 — EBT Margin plunged 24148085 bps — and 2025, when it surged 4090984 bps.
- Tracing ABVC's EBT Margin over 5 years: stood at 1496.5% in 2021, then slumped by 140 bps to 600.69% in 2022, then sank by 3937 bps to 24249.38% in 2023, then plunged by 67 bps to 40515.11% in 2024, then surged by 101 bps to 394.74% in 2025.
- The last three EBT Margin figures came in at 394.74% (Q4 2025), 40515.11% (Q4 2024), and 125.12% (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | Abvc Biopharma | 23.34 Mn | 23.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 394.74% |
| Dec 31, 2024 | -40,515.11% |
| Sep 30, 2024 | -125.12% |
| Jun 30, 2024 | -988.81% |
| Mar 31, 2024 | -242,959.92% |
| Dec 31, 2023 | -24,249.38% |
| Sep 30, 2023 | -21,210.52% |
| Jun 30, 2023 | -36,561.30% |
| Mar 31, 2023 | -1,479.07% |
| Dec 31, 2022 | -600.69% |
| Sep 30, 2022 | -8,924.51% |
| Jun 30, 2022 | -648.78% |
| Mar 31, 2022 | -24,062.67% |
| Dec 31, 2021 | 1,496.50% |
| Sep 30, 2021 | -1,981.75% |
| Jun 30, 2021 | -6,719.00% |
| Mar 31, 2021 | -473.63% |
| Dec 31, 2020 | -8,128.79% |
| Sep 30, 2020 | -1,883.00% |
| Jun 30, 2020 | -985.68% |